The global acute repetitive seizures market size was estimated at USD 140.5 million in 2017 and is expected to register a CAGR of 47.8% over the forecast period. High unmet clinical needs for patients, as well as caregivers, and availability of advanced product pipeline are some of the major factors expected to propel market growth. Drug therapy is effective for most of the patients suffering from cluster seizures. However, there are a significant number of treatment challenges and unmet medical needs including drug-induced seizures, adverse reactions, and lack of antiepileptogenic agents that can prevent the development of seizures and its comorbidities.
In an attempt to curb healthcare expenditure, governments across the globe are making continuous efforts to reduce hospital stays and on-site patient treatment costs through outpatient care models, such as clinic and home healthcare. Emerging economies like India and China are increasingly implementing these healthcare reforms. This factor is expected to propel the growth of acute repetitive seizures market.
The treatment gap is a useful measure to compare access to quality care for patients suffering from seizures. The treatment gap for low- and middle-income countries, such as India, South Africa, and Brazil, is around 80%, while it is around 60% in developed countries, such as U.S. and U.K.
Among the many routes of medicine administration, patients prefer the intranasal route over other types, such as buccal, rectal, and intramuscular route. Parenteral medications have proven to be the optimal option for outpatient treatment. However, in some countries, such as the Netherlands, caregivers are not qualified for administrating parenteral medications.
Based on product, the market is categorized into USL-261, NRL-1, AZ-002, Diastat Rectal Gel {DRG}, and others. Diastat Rectal Gel led the product segment in 2017 owing to its efficiency and lack of FDA-approved drugs in the market. It is the only FDA-approved drug and the generic versions of it were introduced in 2010.
NRL-1 is expected to be the fastest-growing segment over the forecast period. It is an investigational drug developed by Neurelis to be used for children, adolescents, and adults. The company filed NDA with the FDA in September 2018. USL-261 is expected to show lucrative growth over the forecast years and is specifically designed for intranasal administration for outpatient use.
The U.S. held a share of 17.0% in 2017 in the global market. According to the data published by the CDC, around 4.3 million adults and 750,000 children in the U.S. had epilepsy in 2014. Also, the total direct and indirect cost of epilepsy in this region is estimated to be around USD 15.5 billion annually. Thus, the presence of a large target population base for epilepsy drugs in this region will spur the market growth.
Germany is expected to witness robust growth over the forecast period owing to technological advancements in scientific, clinical, and medical fields. Increasing demand for antiepileptic drugs due to rising disease prevalence in the region fosters market growth. Government initiatives, in an attempt to improve the quality of life and awareness regarding the disease, coupled with the promotion of better healthcare facilities are the major drivers boosting the market growth in this region.
The Asia Pacific market is also likely to witness rapid development on account of increasing healthcare expenditure in developing countries, such as India and China. A huge gap was observed in the treatment for acute repetitive seizures in this region. Hence, the demand for the antiseizure drugs in these developing countries encourages a shift in market potential from the already saturated European and North American regions to such economies.
UCB S.A. and Neurelis, Inc. are likely to hold the major share of the global market due to the commercialization of USL-261 and VALTOCO. As both the drugs (USL-261 and VALTOCO) are granted orphan drug designation, the prices will be usually high. In addition, as per our studies, the preferred route of administration is nasal, which in turn will result in higher adoption of these two drugs.
Attribute |
Details |
Base year for estimation |
2017 |
Actual estimates/Historical data |
2013 - 2016 |
Forecast period |
2018 - 2025 |
Market representation |
Revenue in USD Million and CAGR from 2017 to 2025 |
Regional scope |
North America, Europe, and RoW |
Country scope |
U.S., Canada, Germany, and U.K. |
Report coverage |
Revenue forecast, competitive landscape, growth factors, and trends |
15% free customization scope (equivalent to 5 analysts working days) |
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization |
This report forecasts revenue and volume growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2013 to 2025. For the purpose of this study, Grand View Research has segmented the global acute repetitive seizures market report on the basis of product and region:
Product Outlook (Revenue, USD Million, 2013 - 2025)
USL-261
NRL-1
AZ-002
Diastat Rectal Gel
Others
Regional Outlook (Revenue, USD Million, 2013 - 2025)
North America
The U.S.
Canada
Europe
Germany
The U.K.
Rest of World
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.